Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized phase II trial

Annals of Surgical Oncology

Volumn 19, Issue 7, 2012, Pages 2256-2263

  Reni, Michele ^a   Balzano, Gianpaolo ^a   Aprile, Giuseppe ^b   Cereda, Stefano ^a   Passoni, Paolo ^a   Zerbi, Alessandro ^c   Tronconi, Maria Chiara ^d   Milandri, Carlo ^e   Saletti, Piercarlo ^f   Rognone, Alessia ^a   Fugazza, Clara ^a   Magli, Alessandro ^b   Di Muzio, Nadia ^a   Di Carlo, Valerio ^a   Villa, Eugenio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c Pancreatic Surgery Section   (Italy)

^d Istituto Clinico Humanitas   (Italy)

^e DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^f OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RANDOMIZATION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84865142675     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2205-2     Document Type: Article

References (36)

1. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903. (Pubitemid 15040883)
2. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-10. (Pubitemid 38339364)
3. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas and periampul-lary region. Phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-84. (Pubitemid 30191812)
4. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. A randomized controlled trial. JAMA. 2007;297:267-77. (Pubitemid 46143304)
5. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Eg-awa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy for pancreatic cancer. Br J Cancer. 2009;101:908-15.
6. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma. A randomized controlled trial. JAMA. 2008;299:1019-126.
7. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with Fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. A randomized controlled trial. JAMA. 2010;304:1073-81.
8. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern cooperative oncology group trial E2297. J Clin Oncol. 2002;20:3270-5. (Pubitemid 34831525)
9. Rocha Lima CMS, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22: 3776-83. (Pubitemid 41095218)
10. Heinemann V, Quietzch D, Gieseler F, Gonnermann M, Schö-nekäs H, Rost A, et al. A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. J Clin Oncol. 2006;24:3946-52. (Pubitemid 46630743)
11. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-16.
12. Oettle H, Richards DA, Ramanathan R, van Laethem JL, Peeters M, Fuchs M, et al. A phase III trial of pemetrexed plus gemcit-abine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-45. (Pubitemid 41510138)
13. Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss group for clinical cancer research and the central European cooperative oncology group. J Clin Oncol. 2007;25:2212-7. (Pubitemid 46954645)
14. Cunningham D, Chau I, Stocken C, Valle JW, Smith D, Steward W, et al. Phase III randomised comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-8.
15. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxa-liplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern cooperative oncology group. J Clin Oncol. 2009;27:3778-85.
16. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteǹi G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28:1645-51.
17. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National cancer institute of Canada clinical trials group. J Clin Oncol. 2007;25:1960-6. (Pubitemid 46972777)
18. Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, et al. Gemcitabine versus cisplatin, epirubicin, 5-fluorouracil, gemcitabine in advanced pancreatic cancer: a phase III trial. Lancet Oncol. 2005;6:369-76. (Pubitemid 40753742)
19. Reni M, Passoni P, Bonetto E, Balzano G, Panucci MG, Zerbi A, et al. Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarci-noma. Oncology. 2005;68:239-45. (Pubitemid 41158982)
20. Sobin LH, Wittekind CH. Exocrine pancreas. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
21. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagoga-stric cancer. N Engl J Med. 2008;358:36-46.
22. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest. 1990;8:147-59. (Pubitemid 20350387)
23. Reni M, Passoni P, Panucci MG, Nicoletti R, Galli L, Balzano G, et al. Definitive results of phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol. 2001;19:2679-86. (Pubitemid 32441373)
24. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study. Cancer Invest. 2007;25:594-8. (Pubitemid 350135737)
25. Reni M, Cereda S, Bonetto E, Viganò MG, Passoni P, Zerbi A, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2007;59:361-7. (Pubitemid 46025523)
26. Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, et al. A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol. 2012;69:115-23.
27. Reni M, Bonetto E, Cordio S, Passoni P, Milandri C, Cereda S, et al. Quality of life assessment in advanced pancreatic adeno-carcinoma: results from a phase III randomized trial. Pancreatology. 2006;6:454-63. (Pubitemid 44624279)
28. European Agency for the Evaluation of Medical products (EMEA). Note for guidance on evaluation of anticancer medicinal products in man. http://www.emea.eu.int. Accessed 20 April 2007
29. Johnson JR, Williams G, Pazdur R. End points and United States food and drug administration approval of oncology drugs. J Clin Oncol. 2003;21:1404-11. (Pubitemid 46606423)
30. Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG trial Z05031. Ann Oncol. 2011;22:348-54.
31. Marten A, Schmidt J, Debus J, Harig S, Lindel K, Klein J, et al. CapRI: final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-alpha2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). Proc Am Soc Clin Oncol. 2010;28; LBA4012.
32. Van Laethem JL, Hammel P, Mornex F, Azria D, Van Tienhoven G, Vergauwe P, et al. Adjuvant gemcitabine alone versus gem-citabine-based chemoradiation after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol. 2010;28:4450-6.
33. Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13. (Pubitemid 27251144)
34. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouam Y, et al. FOLFIRINOX versus gemcitabine for meta-static pancreatic cancer. N Engl J Med. 2011;364:1817-25.
35. Stocken DD, Büchler MW, Dervenis C, Bassi C, Jeekel H, Kli-nkenbijl JH, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372-81. (Pubitemid 40705002)
36. Reni M. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol. 2010;16: 4883-7.